Device for drug delivery, especially for the delivery of progestins and estrogens

 

The invention relates to a device for the delivery of therapeutically active agent from the controlled release, especially progestin or estrogen over an extended period of time, and above the device consists of a core containing a therapeutically active agent, and a membrane covering above the core, in which the above membrane made of elastomer. According to the invention, the elastomer is an elastomer-based siloxane containing 3,3,3-triptoreline group attached to the Si-atoms of parts of the siloxane. The device has a small cross-section and is easily inserted or easily spryskivaetsya therapeutically active agent. 11 C.p. f-crystals, 2 Il.

Description text in facsimile form (see graphic part).

Claims

1. Device for the delivery of therapeutically active agent from the controlled release over an extended period of time, and the specified device contains a kernel, containing the above-mentioned therapeutically active agent, and a membrane covering above the core, and the above-mentioned membrane made of elastomer-based siloxane, maderera from 1 to 49,85% deputies, associated with the Si atoms in the siloxane units are of 3,3,3-triptoreline group, and that the elastomer obtained either from (i) a mixture consisting of (a) unsubstituted fluorine-based polymer of siloxane and (b) fluorinated polymer-based siloxane, wherein said polymer contains 3,3,3-triptoreline groups associated with the Si atoms of parts of the siloxane, or (ii) a single polymer-based siloxane containing 3,3,3-triptoreline group attached to the Si-atoms of parts of the siloxane, where the specified polymer or mixture of polymers cross-linked bonds with the formation of the elastomer.

2. The device under item 1, characterized in that it is an implantable device intended for subcutaneous administration of an active agent.

3. The device under item 1, characterized in that the polymer mixture is a mixture of a) poly(dimethylsiloxane) and b) poly(dimethylsiloxane), in which from 1 to 49,85% of methyl groups attached to the Si-atoms of parts of the siloxane substituted 3,3,3-triptoreline groups.

4. The device according to p. 3, characterized in that 49,85% of methyl groups in the polymer (b) substituted 3,3,3-triptoreline groups.

5. The device under item 1, characterized in that the elastomeric core is the Omer kernel is PDMS (polydimethylsiloxane).

7. The device under item 5, characterized in that the elastomer core is an elastomer-based siloxane containing 3,3,3-triptoreline group attached to the Si-atoms of parts of the siloxane.

8. The device under item 1, characterized in that therapeutically active agent is a hormone.

9. The device under item 8, wherein the hormone is a progestin or estrogen.

10. The device according to p. 9, wherein the progestin is gestodene.

11. The device according to p. 10, wherein the device is an implant for subcutaneous administration.

12. Device according to any one of the preceding paragraphs, wherein the elastomer contains a filler.

 

Same patents:

The invention relates to medicine, in particular to the gynecologist, and for hormonal contraception

The invention relates to medicine, namely to transdermal devices for the introduction of inhibiting ovulation 17-diacetylmorphine

The invention relates to the field of medicine and relates to a pharmaceutical combination preparation of the two, Packed in spatial terms separately in the same packaging unit, intended for oral administration at a time sequentially hormonal components, which consist, depending on the circumstances, placed in spatial terms separately in one packing unit and retrieved separately daily dosing units, and the first hormonal component as hormonal biologically active substance contains a combination of estrogen and at least sufficient to suppress ovulation dosage gestagenna the drug either in-phase or multi-phase execution, and the second hormonal component as hormonal biologically active substance contains only one estrogen drug, and the first hormonal component covers 23 or 25, and the second hormonal component covers 4-10 daily dosing units, daily dosage units of the first hormonal component does not contain a combination of biogenic estrogen and synthetic estrogen, and the total number of daily dosing

The invention relates to medicine and can be used for the treatment and prevention of viral hepatitis

The invention relates to medicine, namely to the development of compositions of the solutions used during operations on the “open” heart

The invention relates to pharmaceutical industry

The invention relates to medicine and relates, in particular, pharmacology, namely, rectal suppositories, which has anti-inflammatory and analgesic effect, containing the drug nonsteroidal series - indomethacin and the basis, in the following ratio of components, g on one suppository:

Indometacin 0,05-0,1

Aerosil 0,015

Witepsol W35 0,401-0,416

Witepsol H15 0,9360-0,9709

Castor oil 0,039

Urea 0,00105

Nipazol 0,00045

Tween-80 0,00750

Effect: invention allows to provide a high bioavailability of drug substances by rectal way of its introduction into the body, enhances the therapeutic effect of indomethacin, improves its release from the dosage form and the absorption of it in the blood, allows to obtain a stable dispersion system when using small amounts of stabilizers, providing the microbial purity of the drug during storage

The invention relates to medicine, specifically to pharmacology

The invention relates to the creation of hepatoprotective tools
The invention relates to the pharmaceutical industry, namely the creation of pharmaceutical compositions with a wide range of pharmacological actions on derived orotovoy acid

The invention relates to the field of pharmaceutical industry and relates to pharmaceutical compositions on the basis of levothyroxine sodium

The invention relates to the creation of hepatoprotective tools

The invention relates to medicine and relates to a pharmaceutical composition with anti-inflammatory and antiallergic action, including betamethasone dipropionate, a hydrophobic component is a combination of petrolatum, paraffin wax and paraffin oil, antioxidant, water, propylene glycol, Trilon B, emulsifier and ether p-oksibenzoynoy acid

The invention relates to the field of pharmaceutical industry and relates to an aqueous solution containing bile acid, and method of its production

The invention relates to the field of medicine and relates to anti-inflammatory and anti-allergic composition comprising as an active start to the combination of betamethasone dipropionate and salicylic acid as auxiliary substances, liquid paraffin and vaseline
Up!